BC Platforms secures USD $10 million Series B Financing led by Debiopharm and Tesi to further grow its genomic knowledge platform development.

Finland Investments 09 May 2017
Share on FacebookShare on Twitter

BC Platforms, a Lausanne, Switzerland and Helsinki, Finland-based company providing genomic data management solutions, announced that it has closed a $USD 10 million financing round.

The backers include Debiopharm Innovation Fund and Tesi, a Finnish venture capital and private equity company owned by the state, as well as the BC Platforms' existing investors.

BC Platforms will use the funds to launch new technologies in 2017 integrating complex clinical and genomic data in order to deliver precision medicine and clinical patient benefits, as well as to grow its existing genomic data management software business worldwide.

BC Platforms, launched in 1997 and led by CEO Tero Silvola, has developed an analytics platform for healthcare and industry that enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms' vision is to revolutionize decision making in drug development to bring clinical benefits to patients. To date, the company has established partnerships with over 50 enterprise level Healthcare units and biobanks globally in 19 countries representing more than 2 million subjects.